Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley
November 12 2020 - 9:00AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that Dr. Steven O’Day,
Executive Director of the John Wayne Cancer Institute, Dr. Jennifer
Buell, President and COO of Agenus, and Patrick Jordan, COO of
AgenTus Therapeutics, will participate in panel discussions at the
Virtual SITC 2020 Immuno-Oncology Event hosted by B. Riley.
Date: Thursday, November 12,
2020
Panel #2: Next-Gen Checkpoint Inhibitors
(CPI) and Co-Stimulatory Agonists Finally Ready for Prime
Time
Time: 1:00 PM – 2:00 PM
ETConference ID: 311564
Agenus Inc.Steven O’Day, MD –
Executive Director of the John Wayne Cancer InstituteJennifer
Buell, PhD – President & COODhan Chand, PhD – Scientific
Director Head of Drug Discovery
Compass TherapeuticsThomas J.
Schuetz, MD, PhD – Co-Founder & CEO
F-Star TherapeuticsEliot Forster,
PhD – President & CEOLouis Kayitalire, MD – CMO
TRIGR TherapeuticsMiranda Toledano
– COO & CFO
Panel #3: Cell Therapy
2.0: Transforming Immune Cells to Mainstream Cancer
Treatments
Time: 2:00 PM – 3:00 PM
ETConference ID: 650564
Agenus Inc. and AgenTus
TherapeuticsJennifer Buell, PhD – President & COO
(Agenus)Patrick Jordan – COO (AgenTus)
Adicet BioChen
Schor – President & CEOStewart Abbott, PhD – COO & CSO
Mustang
BioManny Litchman, MD – President & CEOKnut
Niss, PhD – CTO
Carisma
TherapeuticsSteven Kelly – President & CEO
GlycostemTroels Jordansen – CEOJan
Spanholtz, PhD – CSO
Replays will be available after the discussions by
dialing 800-332-6854 or 973-528-0005 and entering the corresponding
conference ID. They will also be available on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations
About AgenTus Therapeutics,
Inc.AgenTus Therapeutics is a biopharmaceutical company
focused on the discovery, development, and commercialization of
breakthrough unmodified and modified allogeneic iNKT cells with
engineered receptors, such as T cell receptors (TCRs) and Chimeric
Antigen Receptors (CARs), designed to supercharge the human immune
system cells to seek and destroy cancer. AgenTus also aims to
advance adoptive cell therapy formats which would enable
off-the-shelf living drugs. AgenTus has locations in Lexington, MA
and Cambridge, UK. For more information, please visit
www.agentustherapeutics.com.
About AgenusAgenus is a
clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body's immune system to
fight cancer. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more information, please visit
www.agenusbio.com and our Twitter handle @agenus_bio. Information
that may be important to investors will be routinely posted on our
website and Twitter.
Contact:Agenus
Inc. Caroline
Bafundo212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Oct 2023 to Oct 2024